Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals Plc    HIK   GB00B0LCW083

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

DIRECTOR DEALINGS: Hikma Directors Up Stake As Darhold Buys Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/02/2016 | 07:12pm CET

LONDON (Alliance News) - Hikma Pharmaceuticals PLC on Friday said Darhold Ltd has purchased shares in the company over the past three days, affecting the interests of three board members that hold a stake in Darhold.

Darhold acquired 150,000 shares in Hikma at an average price of 1,679.0 pence over November 30, December 1 and 2.

Chairman and Chief Executive Said Darwazah owns a 21.67% stake in Darhold, Executive Vice Chairman Mazen Darwazah owns a 10.92% stake and Mohammed Al-Husry holds a stake of 8.01%. Hikma did not state what holding Darhold or any of the directors have following the transactions.

Darhold last purchased shares in Hikma in September, paying 2,099.0 pence per share.

Hikma shares closed down 1.9% to 1,641.0 pence per share on Friday.

Copyright 2016 Alliance News Limited. All Rights Reserved.  , source Alliance News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HIKMA PHARMACEUTICALS PLC
12/02 DIRECTOR DEALINGS : Hikma Directors Up Stake As Darhold Buys Shares
11/22 TOP NEWS : Hikma Signs Development And Licensing Deal With Vectura
11/16 HIKMA PHARMACEUTICALS : Additional Listing
11/15 HIKMA PHARMACEUTICALS : *morgan stanley raises hikma to 'overweight' ('equal-w.'..
11/11 HIKMA PHARMACEUTICALS : *jefferies cuts hikma pharmaceutical price target to 200..
11/11 HIKMA PHARMACEUTICALS : *hsbc cuts hikma pharmaceutical price target to 1800 pen..
11/11 HIKMA PHARMACEUTICALS : *s&p global raises hikma to 'strong buy' ('hold') - targ..
11/10 IN THE KNOW : Numis Cuts Forecasts For Hikma After It Trims Guidance
11/10 HIKMA PHARMACEUTICALS : sees lower full-year revenue from generics unit
11/10 TOP NEWS : Hikma Pharmaceuticals Trims Revenue Guidance For 2016
More news
Sector news : Pharmaceuticals - NEC
01:25aDJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/19 Emerging Markets Shake Off Brexit
08/24 Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Q2 2016 Results - Earning..
08/24 Hikma Pharmaceuticals reports H1'16 results
03/16 Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Q4 2015 Results - Earning..
03/16 Hikma Pharmaceuticals reports FY'15 results
Advertisement
Financials ($)
Sales 2016 1 979 M
EBIT 2016 366 M
Net income 2016 154 M
Debt 2016 622 M
Yield 2016 1,04%
P/E ratio 2016 27,96
P/E ratio 2017 15,89
EV / Sales 2016 2,85x
EV / Sales 2017 2,37x
Capitalization 5 017 M
More Financials
Chart HIKMA PHARMACEUTICALS PLC
Duration : Period :
Hikma Pharmaceuticals Plc Technical Analysis Chart | HIK | GB00B0LCW083 | 4-Traders
Full-screen chart
Technical analysis trends HIKMA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 29,5 $
Spread / Average Target 40%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Saaid Samih Taleb Darwazah Chairman & Chief Executive Officer
Khalid Nabilsi Chief Financial Officer
Ibrahim Jalal Senior Vice President-Technical Affairs
Ragheb Al-Shakhshir Vice President-Research & Development
Michael Richard Dwyer Ashton Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
HIKMA PHARMACEUTICALS ..-27.34%5 017
JOHNSON & JOHNSON8.43%303 013
PFIZER INC.-2.54%190 910
ROCHE HOLDING LTD.-17.98%189 262
NOVARTIS AG-19.07%177 818
MERCK & CO., INC.15.85%167 524
More Results